Currently, tissue plasminogen activator (tPA) is the only FDA-approved pharmacologic treatment for ischemic or thrombotic stroke, which carries the risk of producing an intracerebral hemorrhage [2,3,4]. This evidence concerns the gene PLAT and intracerebral hemorrhage.